SCHEMBL6769706

SCHEMBL6769706

CCCNCc1c(C(=O)O)nn(-c2ccccc2Cl)c1Oc1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.41
PDE4B Q07343 1/20 0.41
CNR1 P21554 14/20 0.40
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
CNR2 P34972 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6770852 0.92 PDE4B (0.48) KMT2APDE4BCNR1KDM4EMAPT
SCHEMBL6770604 0.90 CNR1 (0.45) CNR1CNR2
SCHEMBL6770373 0.89 CNR1 (0.51) CNR1CNR2
SCHEMBL6766497 0.89 CNR1 (0.47) CNR1CNR2
SCHEMBL6777628 0.88 CNR2 (0.47) CNR1CNR2
SCHEMBL6770293 0.87 CNR2 (0.45) CNR1CNR2
SCHEMBL5768742 0.87 CNR1 (0.47) CNR1
SCHEMBL6769675 0.86 CNR1 (0.55) CNR1CNR2
SCHEMBL6768892 0.86 CNR1 (0.43) KMT2APDE4BCNR1KDM4EMAPT
SCHEMBL6765770 0.86 PDE4B (0.46) PDE4BCNR1MAPTCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235926-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC. 2004-11-25 US claimed
US-20040235926-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC. 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235926-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 KMT2A 3731/4885PDE4B 2564/4885CNR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.